Why the study?
Does pegylated-liposomal doxorubicin improve outcomes in patients with AIDS-related Kaposi's sarcoma after failure of standard chemotherapy?
Does pegylated-liposomal doxorubicin improve outcomes in patients with AIDS-related Kaposi's sarcoma after failure of standard chemotherapy?
Pegylated-liposomal doxorubicin may serve as an alternative treatment for AIDS-related Kaposi's sarcoma following the failure of standard chemotherapy.
May warrant consideration in refractory AIDS-KS; leaves open need for randomized confirmation.
Pegylated-liposomal doxorubicin offers a new alternative for treatment of patients who have experienced failure of standard chemotherapy for AIDS-KS.
No takes yet. Share an insight, caveat, or question.
Northfelt et al. (1997) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: